Cord Blood Hematopoietic Cell Transplantation

Thomas' Hematopoietic Cell Transplantation: Stem Cell Transplantation, Fourth Edition

Volumn , Issue , 2009, Pages 559-576

  Broxmeyer, Hal E ^a   Smith, Franklin O ^b  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

Cord blood hematopoietic cell transplantation; Gene therapy of UCB stem cells; History of UCB transplantation; Immune reconstitution after UCB transplantation; Related donor UCB transplantation; Searching for UCB donor; UCB banking; Umbilical cord blood (UCB) hematopoietic cells alternative source of hematopoietic stem cells (HSCs); Unrelated donor UCB transplantation

Indexed keywords

EID: 72449178064     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781444303537.ch39     Document Type: Chapter

References (237)

1. McCullough J, Hansen J, Perkins H, Stroncek D, Bartsch G. The National Marrow Donor Program: how it works, accomplishments to date. Oncology 1989; 3: 63-8; discussion 72-4.
2. Perkins HA, Hansen JA. The US National Marrow Donor Program. Am J Pediatr Hematol Oncol 1994; 16: 30-4.
3. Kernan NA, Bartsch G, Ash RC et al. Analysis of 462 transplantations from unrelated donors facilitated by the National Marrow Donor Program. N Engl J Med 1993; 328: 593-602. 4 Broxmeyer HE. Introduction. The past, present, and future of cord blood transplantation. In: Broxmeyer HE, editor. Cellular Characteristics of Cord Blood and Cord Blood Transplantation. Bethesda, MD: AABB Press; 1998. pp. 1-9.
4. Broxmeyer HE. Introduction. Cord blood transplantation: looking back and to the future. In: Cohen SBA, Gluckman E, Rubinstein P, Madrigal JA, editors. Cord Blood Characteristics: Role in Stem Cell Transplantation. London: Dunitz; 1998 pp. 1-12.
5. Broxmeyer HE, Douglas GW, Hangoc G et al. Human umbilical cord blood as a potential source of transplantable hematopoietic stem/progenitor cells. Proc Natl Acad Sci U S A 1989; 86: 3828-32.
6. Broxmeyer HE, Kurtzberg J, Gluckman E et al. Umbilical cord blood hematopoietic stem and repopulating cells in human clinical transplantation. Blood Cells 1991; 17: 313-29.
7. Broxmeyer HE, Hangoc G, Cooper S et al. Growth characteristics and expansion of human umbilical cord blood and estimation of its potential for transplantation in adults. Proc Natl Acad Sci U S A 1992; 89: 4109-13.
8. Gluckman E, Broxmeyer HA, Auerbach AD et al. Hematopoietic reconstitution in a patient with Fanconi's anemia by means of umbilical-cord blood from an HLA-identical sibling. N Engl J Med 1989; 321: 1174-8.
9. Broxmeyer HE, Gluckman E, Auerbach A et al. Human umbilical cord blood: a clinically useful source of transplantable hematopoietic stem/progenitor cells. Int J Cell Cloning 1990; 8(Suppl 1): 76-89; discussion 89-91.
10. Wagner JE, Broxmeyer HE, Byrd RL et al. Transplantation of umbilical cord blood after myeloablative therapy: analysis of engraftment. Blood 1992; 79: 1874-81.
11. Kohli-Kumar M, Shahidi NT, Broxmeyer HE et al. Haemopoietic stem/progenitor cell transplant in Fanconi anaemia using HLA-matched sibling umbilical cord blood cells. Br J Haematol 1993; 85: 419-22.
12. Vilmer E, Sterkers G, Rahimy C et al. HLAmismatched cord-blood transplantation in a patient with advanced leukemia. Transplantation 1992; 53: 1155-7.
13. Wagner JE, Kernan NA, Steinbuch M, Broxmeyer HE, Gluckman E. Allogeneic sibling umbilicalcord- blood transplantation in children with malignant and non-malignant disease. Lancet 1995; 346: 214-19.
14. Brunstein CG, Setubal DC, Wagner JE. Expanding the role of umbilical cord blood transplantation. Br J Haematol 2007; 137: 20-35.
15. Hayani A, Lampeter E, Viswanatha D, Morgan D, Salvi SN. First report of autologous cord blood transplantation in the treatment of a child with leukemia. Pediatrics 2007; 119: 296-300.
16. Ferreira E, Pasternak J, Bascal N, de Campos Guerra JC, Mitie Watanabe F. Autologous cord blood transplantation. Bone Marrow Transplant 1999; 24: 1041.
17. Fruchtman SM, Hurlet A, Dracker R et al. The successful treatment of severe aplastic anemia with autologous cord blood transplantation. Biol Blood Marrow Transplant 2004; 10: 741-2.
18. Reed W, Smith R, Dekovic F et al. Comprehensive banking of sibling donor cord blood for children with malignant and nonmalignant disease. Blood 2003; 101: 351-7.
19. Smythe J, Armitage S, McDonald D et al. Directed sibling cord blood banking for transplantation: the 10-year experience in the national blood service in England. Stem Cells 2007; 25: 2087-93.
20. American Academy of Pediatrics. Policy Statement. Cord blood banking for potential future transplantation. Pediatrics 2007; 119: 165-70.
21. Scaradavou A, Carrier C, Mollen N, Stevens C, Rubinstein P. Detection of maternal DNA in placental/ umbilical cord blood by locus-specific amplification of the noninherited maternal HLA gene. Blood 1996; 88: 1494-500.
22. Ballen KK, Wilson M, Wuu J et al. Bigger is better: maternal and neonatal predictors of hematopoietic potential of umbilical cord blood units. Bone Marrow Transplant 2001; 27: 7-14.
23. Pafumi C, Zizza G, Russo A et al. Placing the newborn on the maternal abdomen increases the volume of umbilical cord blood collected. Clin Lab Haematol 2001; 23: 397-9.
24. Yamada T, Okamoto Y, Kasamatsu H, Horie Y, Yamashita N, Matsumoto K. Factors affecting the volume of umbilical cord blood collections. Acta Obstet Gynecol Scand 2000; 79: 830-3.
25. Surbek DV, Visca E, Steinmann C et al. Umbilical cord blood collection before placental delivery during cesarean delivery increases cord blood volume and nucleated cell number available for transplantation. Am J Obstet Gynecol 2000; 183: 218-21.
26. Surbek DV, Aufderhaar U, Holzgreve W. Umbilical cord blood collection for transplantation: which technique should be preferred? Am J Obstet Gynecol 2000; 183: 1587-8.
27. Ballen KK, Hicks J, Dharan B et al. Racial and ethnic composition of volunteer cord blood donors: comparison with volunteer unrelated marrow donors. Transfusion 2002; 42: 1279-84.
28. Elchalal U, Fasouliotis SJ, Shtockheim D et al. Postpartum umbilical cord blood collection for transplantation: a comparison of three methods. Am J Obstet Gynecol 2000; 182: 227-32.
29. Hiett AK, Britton KA, Hague NL, Brown HL, Stehman FB, Broxmeyer HE. Comparison of hematopoietic progenitor cells in human umbilical cord blood collected from neonatal infants who are small and appropriate for gestational age. Transfusion 1995; 35: 587-91.
30. George TJ, Sugrue MW, George SN, Wingard JR. Factors associated with parameters of engagement potential of umbilical cord blood. Transfusion 2006; 46: 1803-12.
31. Cairo MS, Wagner EL, Fraser J et al. Characterization of banked umbilical cord blood hematopoietic progenitor cells and lymphocyte subsets and correlation with ethnicity, birth weight, sex, and type of delivery: a Cord Blood Transplantation (COBLT) Study report. Transfusion 2005; 45: 856-66.
32. Kurtzberg J, Cairo MS, Fraser JK et al. Results of the cord blood transplantation (COBLT) study unrelated donor banking program. Transfusion 2005; 45: 842-55.
33. American College of Obstetricians and Gynecologists Committee opinion. Routine storage of umbilical cord blood for potential future transplantation. Int J Gynaecol Obstet 1997; 58: 257-9.
34. American Academy of Pediatrics Work Group on Cord Blood Banking. Cord blood banking for potential future transplantation: subject review. Pediatrics 1999; 104: 116-18.
35. McCullough J, Clay M. Reasons for deferral of potential umbilical cord blood donors. Transfusion 2000; 40: 124-5.
36. Jeffries LC, Alberto M, Morgan MA, Muolten D. High deferral rate for maternal-neonatal donor pairs for an allogeneic umbilical cord blood bank. Transfusion 1999; 39: 415-19.
37. Lecchi L, Rebulla P, Ratti I et al. Outcomes of a program to evaluate mother and baby 6 months after umbilical cord blood donation. Transfusion 2001; 41: 606-10.
38. Gluckman E. Cord blood banking and transplantation in Europe. In: Broxmeyer HE, editor. Cellular Characteristics of Cord Blood and Cord Blood Transplantation. Bethesda, MD: AABB Press; 1998. pp. 147-64.
39. Peterson RK, Clay M, McCullough J. Unrelated cord blood baking. In: Broxmeyer HE, editor. Cellular Characteristics of Cord Blood and Cord Blood Transplantation. Bethesda, MD: AABB Press; 1998. pp. 165-97.
40. Rubinstein P, Rosenfield RE, Adamson JW, Stevens CE. Stored placental blood for unrelated bone marrow reconstitution. Blood 1993; 81: 1679-90.
41. Rubinstein P, Taylor PE, Scaradavou A et al. Unrelated placental blood for bone marrow reconstitution: organization of the placental blood program [see comments]. Blood Cells 1994; 20: 587-600.
42. Pafumi C, Bosco P, Cavallaro A et al. Two CD34+ stem cells from umbilical cord blood enrichment methods. Pediatr Hematol Oncol 2002; 19: 239-45.
43. Kato S, Nishihira H, Hara H et al. Cord blood transplantation and cord blood bank in Japan. Bone Marrow Transplant 2000; 25 (Suppl 2): S68-70.
44. Donaldson C, Buchanan R, Webster J et al. Development of a district Cord Blood Bank: a model for cord blood banking in the National Health Service. Bone Marrow Transplant 2000; 25: 899-905.
45. Vawter DE, Rogers-Chrysler G, Clay M et al. A phased consent policy for cord blood donation. Transfusion 2002; 42: 1268-74.
46. Askari S, Miller J, Clay M, Moran S, Chrysler G, McCullough J. The role of the paternal health history in cord blood banking. Transfusion 2002; 42: 1275-8.
47. Rubinstein P, Dobrila L, Rosenfield RE et al. Processing and cryopreservation of placental/ umbilical cord blood for unrelated bone marrow reconstitution. Proc Natl Acad Sci U S A 1995; 92: 10119-22.
48. Denning-Kendall P, Donaldson C, Nicol A, Bradley B, Hows J. Optimal processing of human umbilical cord blood for clinical banking. Exp Hematol 1996; 24: 1394-401.
49. Nagler A, Peacock M, Tantoco M, Lamons D, Okarma TB, Okrongly DA. Separation of hematopoietic progenitor cells from human umbilical cord blood. J Hematother 1993; 2: 243-5.
50. Newton I, Charbord P, Schaal JP, Herve P. Toward cord blood banking. Density-separation and cryo-preservation of cord blood progenitors. Exp Hematol 1993; 21: 671-4.
51. Pollack MS, Auerbach AD, Broxmeyer HE, Zaafran A, Griffith RL, Erlich HA. DNA amplification for DQ typing as an adjunct to serological prenatal HLA typing for the identification of potential donors for umbilical cord blood transplantation. Hum Immunol 1991; 30: 45-9.
52. Trachtenberg EA, Erlich HA. DNA-based HLA typing for cord blood stem cell transplantation. J Hematother 1996; 5: 295-300.
53. Liao C, Wu JY, Xu ZP et al. Indiscernible benefit of high-resolution HLA typing in improving longterm clinical outcome of unrelated umbilical cord blood transplant. Bone Marrow Transplant 2007; 40: 201-8.
54. Bochtler W, Maiers M, Oudshoorn M et al. World Marrow Donor Association guidelines for use of HLA nomenclature and its validation in the data exchange among hematopoietic stem cell donor registries and cord blood banks. Bone Marrow Transplant 2007; 39: 737-41.
55. Broxmeyer HE, Srour EF, Hangoc G, Cooper S, Anderson JA, Bodine D. High efficiency recovery of hematopoietic progenitor cells with extensive proliferative and ex-vivo expansion activity and of hematopoietic stem cells with NOD/SCID mouse repopulation ability from human cord blood stored frozen for 15 years. Proc Natl Acad Sci U S A 2003; 100: 645-50.
56. Broxmeyer HE, Cooper S. High-efficiency recovery of immature haematopoietic progenitor cells with extensive proliferative capacity from human cord blood cryopreserved for 10 years. Clin Exp Immunol 1997; 107(Suppl 1): 45-53.
57. Lu L, Ge Y, Li ZH, Freie B, Clapp DW, Broxmeyer HE. CD34 stem/progenitor cells purified from cryopreserved normal cord blood can be transduced with high efficiency by a retroviral vector and expanded ex vivo with stable integration and expression of Fanconi anemia complementation C gene. Cell Transplant 1995; 4: 493-503.
58. DiGiusto DL, Lee R, Moon J et al. Hematopoietic potential of cryopreserved and ex vivo manipulated umbilical cord blood progenitor cells evaluated in vitro and in vivo. Blood 1996; 87: 1261-71.
59. Kurtzberg J, Lyerly AD, Sugarman J. Untying the Gordian knot: policies, practices, and ethical issues related to banking of umbilical cord blood. J Clin Invest 2005; 115: 2592-7.
60. Beatty PG, Boucher KM, Mori M, Milford EL. Probability of finding HLA-mismatched related or unrelated marrow or cord blood donors. Hum Immunol 2000; 61: 834-40.
61. Barker JN, Krepski TP, DeFor TE, Davies SM, Wagner JE, Weisdorf DJ. Searching for unrelated donor hematopoietic stem cells. Availability and speed of umbilical cord blood versus bone marrow. Biol Blood Marrow Transplant 2002; 8: 257-60.
62. Rocha V, Cornish J, Sievers EL et al. Comparison of outcomes of unrelated bone marrow and umbilical cord blood transplants in children with acute leukemia. Blood 2001; 97: 2962-71.
63. Meyer EA, Hanna K, Gebbre K, editors. Cord Blood: Establishing a National Hematopoietic Stem Cell Bank Program. Washington, DC: National Academies Press; 2005.
64. Gluckman E, Rocha V, Boyer-Chammard A et al. Outcome of cord-blood transplantation from related and unrelated donors. EUROCORD Transplant Group and the European Blood and Marrow Transplantation Group. N Engl J Med 1997; 337: 373-81.
65. Rocha V, Wagner JE, Sobocinski KA et al. Graftversus- host disease in children who received a cord-blood or bone marrow transplant from an HLA-identical sibling. New Engl J Med 2000; 342: 1846-54.
66. Rubinstein P, Carrier C, Scaradavou A et al. Outcomes among 562 recipients of placental-blood transplants from unrelated donors. N Engl J Med 1998; 339: 1565-77.
67. Thomson BG, Robertson KA, Gowan D et al. Analysis of engraftment, graft-versus-host disease, and immune recovery following unrelated donor cord blood transplantation. Blood 2000; 96: 2703-11.
68. Cornetta K, Laughlin M, Carter S et al. Umbilical cord blood transplantation in adults: results of the prospective Cord Blood Transplantation (COBLT). Biol Blood Marrow Transplant 2005; 11: 149-60.
69. Martin PL, Carter SL, Kernan NA et al. Results of the Cord Blood Transplantation Study (COBLT): outcomes of unrelated donor umbilical cord blood transplantation in pediatric patients with lysosomal and peroxisomal storage diseases. Biol Blood Marrow Transplant 2006; 12: 184-94.
70. Wall DA, Carter SL, Kernan NA et al. Busulfan/ melphalan/antithymocyte globulin followed by unrelated donor cord blood transplantation for treatment of infant leukemia and leukemia in young children: the Cord Blood Transplantation study (COBLT) experience. Biol Blood Marrow Transplant 2005; 11: 637-46.
71. Rubinstein P, Stevens CE. Placental blood for bone marrow replacement. The New York Blood Center's program and clinical results. Baillieres Best Pract Res Clin Haematol 2000; 13: 565-84.
72. Kurtzberg J, Laughlin M, Graham ML et al. Placental blood as a source of hematopoietic stem cells for transplantation into unrelated donors [see comments]. N Engl J Med 1996; 335: 157-66.
73. Barker JN, Davies SM, DeFor T, Ramsay NK, Weisdorf DJ, Wagner JE. Survival after transplantation of unrelated donor umbilical cord blood is comparable to that of human leukocyte antigen-matched unrelated donor bone marrow: results of a matched-pair analysis. Blood 2001; 97: 2957-61.
74. Gluckman E, Rocha V, Chevret S. Results of unrelated umbilical cord blood hematopoietic stem cell transplant. Transfus Clin Biol 2001; 8: 146-54.
75. Eapen M, Rubinstein P, Zhang MJ et al. Comparable long-term survival after unrelated and HLAmatched sibling donor hematopoietic stem cell transplantation for acute leukemia in children younger than 18 months. J Clin Oncol 2006; 24: 145-51.
76. Hwang WYK, Samuel M, Tan D et al. A metaanalysis of unrelated donor umbilical cord blood transplantation versus unrelated donor bone marrow transplantation in adult and pediatric patients. Biol Blood Marrow Transplant 2007; 13: 444-53.
77. Laughlin MJ, Barker J, Bambach B et al. Hematopoietic engraftment and survival in adult recipients of umbilical-cord blood from unrelated donors. N Engl J Med 2001; 344: 1815-22.
78. Sanz GF, Saavedra S, Jimenez C et al. Unrelated donor cord blood transplantation in adults with chronic myelogenous leukemia: results in nine patients from a single institution. Bone Marrow Transplant 2001; 27: 693-701.
79. Ooi J, Iseki T, Takahashi S et al. A clinical comparison of unrelated cord blood transplantation and unrelated bone marrow transplantation for adult patients with acute leukaemia in complete remission. Br J Haematol 2002; 118: 140-3.
80. Sanz GF, Saavedra S, Planelles D et al. Standardized, unrelated donor cord blood transplantation in adults with hematologic malignancies. Blood 2001; 98: 2332-8.
81. Majhail NS, Weisdorf DJ, Wagner JE et al. Comparable results of umbilical cord blood and HLAmatched sibling donor hematopoietic stem cell transplantation after reduced-intensity preparative regimen for advanced Hodgkin lymphoma. Blood 2006; 107: 3804-7.
82. Laughlin MJ, Eapen M, Rubinstein P et al. Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia. N Engl J Med 2004; 351: 2265-75.
83. Brunstein CG, Barker JN, Weisdorf DJ et al. Umbilical cord blood transplantation after nonmyeloablative conditioning: impact on transplantation outcomes in 110 adults with hematologic disease. Blood 2007; 110: 3064-70.
84. Barker JN, Weisdorf DJ, Defor TE et al. Transplantation of 2 partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy. Blood 2005; 105: 1343-7.
85. Ballen KK, Spitzer TR, Yeap BY et al. Double unrelated reduced-intensity umbilical cord blood transplantation in adults. Biol Blood Marrow Transplant 2007; 13: 82-9.
86. Niehues T, Rocha V, Filipovich AH et al. Factors affecting lymphocyte subset reconstitution after either related or unrelated cord blood transplantation in children: a EUROCORD analysis. Br J Haematol 2001; 114: 42-8.
87. Giraud P, Thuret I, Reviron D et al. Immune reconstitution and outcome after unrelated cord blood transplantation: a single paediatric institution experience. Bone Marrow Transplant 2000; 25: 53-7.
88. Klein AK, Patel DD, Gooding ME et al. T-cell recovery in adults and children following umbilical cord blood transplantation. Biol Blood Marrow Transplant 2001; 7: 454-66.
89. Weinberg K, Blazar BR, Wagner JE et al. Factors affecting thymic function after allogeneic hematopoietic stem cell transplantation. Blood 2001; 97: 1458-66.
90. Talvensaari K, Clave E, Douay C et al. A broad T-cell repertoire diversity and an efficient thymic function indicate a favorable long-term immune reconstitution after cord blood stem cell transplantation. Blood 2002; 99: 1458-64.
91. Smith F, Thomson B. Immune reconstitution and stem cell sources. Pediatric Pathol Mol Med 2000; 19: 187-203.
92. Parkman R, Cohen G, Carter SL et al. Successful immune reconstitution decreases leukemia relapse and improves survival in recipients of unrelated cord blood transplantation. Biol Blood Marrow Transplant 2006; 12: 919-27.
93. Cohen G, Carter SL, Weinberg KI et al. Antigenspecific T-lymphocyte function after cord blood transplantation. Biol Blood Marrow Transplant 2006; 12: 1335-42.
94. Michel G, Rocha V, Chevret S et al. Unrelated cord blood transplantation for childhood acute myeloid leukemia: a Eurocord Group analysis. Blood 2003; 102: 4290-7.
95. Brunstein CG, Wagner JE. Cord Blood transplantation for adults. Vox Sang 2006; 91: 195-205.
96. Shpall EJ, Quinones R, Giller R et al. Transplantation of ex-vivo expanded cord blood. Biol Blood Marrow Transplant 2002; 8: 368-76.
97. Hofmeister CC, Zhang J, Knight KL, Le P, Stiff PJ. Ex vivo expansion of umbilical cord blood stem cells for transplantation: growing knowledge from hematopoietic niche. Bone Marrow Transplant 2007; 29: 11-23.
98. Migliaccio AR, Adamson JW, Stevens CE et al. Cell dose and speed of engraftment in placental/ umbilical cord blood transplantation: graft progenitor cell content is a better predictor than nucleated cell quantity. Blood 2000; 96: 2717-22.
99. Broxmeyer HE. Phenotypic and proliferative characteristics of cord blood hematopoietic stem and progenitor cells and gene transfer. In: Broxmeyer HE, editor. Cellular Characteristics of Cord Blood and Cord Blood Transplantation. Bethesda, MD: AABB Press; 1998. pp. 11-43.
100. Lansdorp PM, Dragowska W, Mayani H. Ontogeny-related changes in proliferative potential of human hematopoietic cells. J Exp Med 1993; 178: 787-91.
101. Lu L, Xiao M, Shen RN, Grigsby S, Broxmeyer HE. Enrichment, characterization, and responsiveness of single primitive CD34 human umbilical cord blood hematopoietic progenitors with high proliferative and replating potential. Blood 1993; 81: 41-8.
102. Carow CE, Hangoc G, Cooper SH, Williams DE, Broxmeyer HE. Mast cell growth factor (c-kit ligand) supports the growth of human multipotential progenitor cells with a high replating potential. Blood 1991; 78: 2216-21.
103. Carow CE, Hangoc G, Broxmeyer HE. Human multipotential progenitor cells (CFU-GEMM) have extensive replating capacity for secondary CFU-GEMM. An effect enhanced by cord blood plasma. Blood 1993; 81: 942-9.
104. Vormoor J, Lapidot T, Pflumio F et al. Immature human cord blood progenitors engraft and proliferate to high levels in severe combined immunodeficient mice. Blood 1994; 83: 2489-97.
105. Bock TA, Orlic D, Dunbar CE, Broxmeyer HE, Bodine DM. Improved engraftment of human hematopoietic cells in severe combined immunodeficient (SCID) mice carrying human cytokine transgenes. J Exp Med 1995; 182: 2037-43.
106. Bhatia M, Wang JC, Kapp U, Bonnet D, Dick JE. Purification of primitive human hematopoietic cells capable of repopulating immune-deficient mice. Proc Natl Acad Sci U S A 1997; 94: 5320-5.
107. Wang JC, Doedens M, Dick JE. Primitive human hematopoietic cells are enriched in cord blood compared with adult bone marrow or mobilized peripheral blood as measured by the quantitative in vivo SCID-repopulating cell assay. Blood 1997; 89: 3919-24.
108. Vaziri H, Dragowska W, Allsopp RC, Thomas TE, Harley UCB, Lansdorp PM. Evidence for a mitotic clock in human hematopoietic stem cells. Loss of telomeric DNA with age. Proc Natl Acad Sci U S A 1994; 91: 9857-60.
109. Kanamaru S, Kawano Y, Watanabe T et al. Low numbers of megakaryocyte progenitors in grafts of cord blood cells may result in delayed platelet recovery after cord blood cell transplant. Stem Cells 2000; 18: 190-5.
110. Bornstein R, Garcia-Vela J, Gilsanz F, Auray C, Cales C. Cord blood megakaryocytes do not complete maturation, as indicated by impaired establishment of endomitosis and low expression of G1/S cyclins upon thrombopoietin-induced differentiation. Br J Haematol 2001; 114: 458-65.
111. Broxmeyer HE, Srour E, Orschell C et al. Cord blood-derived stem and progenitor cells. In: Klimanskaya I, Lanza R, editors. Methods in Enzymology. Vol. 419. San Diego, CA: Academic Press/Elsevier Science; 2006. pp. 439-73.
112. Spangrude GJ, Heimfeld S, Weissman IL. Purifi- cation and characterization of mouse hematopoietic stem cells. Science 1988; 241: 58-62.
113. Uchida N, Weissman IL. Searching for hematopoietic stem cells: evidence that Thy-1.1loLin- Sca-1+ cells are the only stem cells in C57BL/ Ka-Thy-1.1 bone marrow. J Exp Med 1992; 175: 175-84.
114. Morrison SJ, Wandycz AM, Hemmati HD, Wright DE, Weissman IL. Identification of a lineage of multipotent hematopoietic progenitors. Development 1997; 124: 1929-39.
115. Kiel MJ, Yilmaz OH, Iwashita T, Yilmaz OH, Terhorst C, Morrison SJ. SLAM family receptors distinguish hematopoietic stem and progenitor cells and reveal endothelial niches for stem cells. Cell 2005; 121: 1109-21.
116. Kim I, He S, Yilmaz OH, Kiel MJ, Morrison SJ. Enhanced purification of fetal liver hematopoietic stem cells using SLAM family receptors. Blood 2006; 108: 737-44.
117. Akashi K, Traver D, Miyamoto T, Weissman IL. A clonogenic common myeloid progenitor that gives rise to all myeloid lineages. Nature 2000; 404: 193-7.
118. Kondo M, Weissman IL, Akashi K. Identification of clonogenic common lymphoid progenitors in mouse bone marrow. Cell 1997; 91: 661-72.
119. Iwasaki H, Akashi K. Myeloid lineage commitment from the hematopoietic stem cell. Immunity 2007; 26: 726-40.
120. Hao QL, Zhu J, Price MA, Payne KJ, Barsky LW, Crooks GM. Identification of a novel, human multi-lymphoid progenitor in cord blood. Blood 2001; 97: 3683-90.
121. Phillips RL, Ernst RE, Brunk B et al. The genetic program of hematopoietic stem cells. Science 2000; 288: 1635-40.
122. Ramalho-Santos M, Yoon S, Matsuzaki Y, Mulligan RC, Melton DA. "Stemness": transcriptional profiling of embryonic and adult stem cells. Science 2002; 298: 597-600.
123. Ivanova NB, Dimos JT, Schaniel C, Hackney JA, Moore KA, Lemischka IR. A stem cell molecular signature. Science 2002; 298: 601-4.
124. Tao W, Hangoc G, Hawes JW, Si Y, Cooper S, Broxmeyer HE. Profiling of differentially expressed apoptosis-related genes by cDNA arrays in human cord blood CD34+ cells treated with VP- 16 etoposide. Exp Hematol 2003; 31: 251-60.
125. Tao W, Broxmeyer HE. Towards a molecular understanding of hematopoietic stem and progenitor cells. In: Broxmeyer HE, editor. Cord Blood: Biology, Immunology, Banking, and Clinical Transplantation. Bethesda, MD: AABB Press; 2004. pp. 87-123.
126. Tao W, Wang M, Voss ED et al. Comparative proteomic analysis of human CD34+ stem/progenitor cells and mature CD15+ myeloid cells. Stem Cells 2004; 22: 1003-14.
127. Baharvand H, Fathi A, van Hoof D, Salekdeh GH. Concise review: Trends in stem cell proteomics. Stem Cells 2007; 25: 1888-903.
128. Ingram D, Mead L, Tanaka H et al. Identification of a novel hierarchy of endothelial progenitor cells using human peripheral and umbilical cord blood. Blood 2004; 104: 2752-60.
129. Yoder MC, Mead LE, Prater D et al. Redefining endothelial progenitor cells via clonal analysis and hematopoietic stem/progenitor cell principals. Blood 2007; 109: 1801-9.
130. Javazon EH, Beggs KJ, Flake AW. Mesenchymal stem cells: paradoxes of passaging. Exp Hematol 2004; 32: 414-25.
131. Erices A, Conget P, Minguell JJ. Mesenchymal progenitor cells in human umbilical cord blood. Br J Haematol 2000; 109: 235-42.
132. Goodwin HS, Bicknese AR, Chien SN et al. Multilineage differentiation activity by cells isolated from umbilical cord blood: expression of bone, fat and neural markers. Biol Blood Marrow Transplant 2001; 7: 581-8.
133. Bieback K, Kern S, Kluter H, Eichler H. Critical parameters for the isolation of mesenchymal stem cells from umbilical cord blood. Stem Cells 2004; 22: 625-34.
134. Yang S-E, Ha C-W, Jung MH et al. Mesenchymal stem/progenitor cells developed in cultures from UC blood. Cytotherapy 2004; 6: 476-86.
135. Lee OK, Kuo TK, Chen W-M, Lee KD, Hsieh SL, Chen TH. Isolation of multipotent mesenchymal stem cells from umbilical cord blood. Blood 2004; 103: 1669-75.
136. Rosada C, Justesen J, Melsvik D, Ebbesen P, Kassem M. The human umbilical cord blood: a potential source for osteoblast progenitor cells. Calcif Tissue Int 2003; 72: 135-42.
137. Bonanno G, Perillo A, Rutella S et al. Clinical isolation and functional characterization of cord blood CD133+ hematopoietic progenitor cells. Transfusion 2004; 44: 1087-97.
138. Gutierrez-Rodriguez M, Reyes-Maldonado E, Mayani H. Characterization of the adherent cells developed in Dextertype long-term cultures from human umbilical cord blood. Stem Cells 2000; 18: 45-52.
139. Mareschi K, Biasin E, Piacibello W et al. Isolation of human mesenchymal stem cells: bone marrow versus umbilical cord blood. Haematologica 2001; 86: 1099-100.
140. Wexler S, Donaldson C, Denning-Kendall P et al. Adult bone marrow is a rich source of human mesenchymal "stem" cells but umbilical cord and mobilized adult blood are not. Br J Haematol 2003; 121: 368-74.
141. Markov V, Kusumi K, Tadesse MG et al. Identification of cord blood-derived mesenchymal stem/ stromal cell populations with distinct growth kinetics, differentiation potentials, and gene expression profiles. Stem Cells Dev 2007; 16: 53-73.
142. Dorrell C, Gan OI, Pereira DS, Hawley RG, Dick JE. Expansion of human cord blood CD34+CD38- cells in ex vivo culture during retroviral transduction without a corresponding increase in SCID repopulating cell (SRC) frequency: dissociation of SRC phenotype and function. Blood 2000; 95: 102-10.
143. Shaheen M, Broxmeyer HE. The humoral regulation of hematopoiesis. In: Hoffman R, Benz E, Shattil S et al., editors. Hematology: Basic Principles and Practice, 5th edn. Philadelphia: Elsevier/Churchill Livingstone (in press).
144. Broxmeyer HE, Mejia JAH, Hangoc G, Barese C, Dinauer M, Cooper S. SDF-1/CXCL12 enhances in vitro replating capacity of murine and human multipotential and macrophage progenitor cells. Stem Cells Dev 2007; 16: 589-96.
145. Tothova Z, Gilliland DG. FoxO transcription factors and stem cell homeostasis: insights from the hematopoietic system. Cell Stem Cell 2007; 1: 140-52.
146. Chua K-N, Chai C, Lee P-C et al. Functional nanofiber scaffolds with different spacers modulate adhesion and expansion of cryopreserved umbilical cord blood hematopoietic stem/ progenitor cells. Exp Hematol 2007; 35: 771-81.
147. Giarratana M-C, Kobari L, Lapillonne H et al. Ex vivo generation of fully mature human red blood cells from hematopoietic stem cells. Nat Biotech 2005; 23: 69-74.
148. Moritz T, Keller DC, Williams DA. Human cord blood cells as targets for gene transfer: potential use in genetic therapies of severe combined immunodeficiency disease. J Exp Med 1993; 178: 529-36.
149. Lu L, Xiao M, Clapp DW, Li ZH, Broxmeyer HE. High efficiency retroviral mediated gene transduction into single isolated immature and replatable CD343+ hematopoietic stem/progenitor cells from human umbilical cord blood. J Exp Med 1993; 178: 2089-96.
150. Abonour R, Williams DA, Einhorn L et al. Efficient retrovirus-mediated transfer of the multidrug resistance 1 gene into autologous human longterm repopulating hematopoietic stem cells. Nat Med 2000; 6: 652-8.
151. Kohn DB, Weinberg KI, Nolta JA et al. Engraftment of gene-modified umbilical cord blood cells in neonates with adenosine deaminase deficiency. Nat Med 1995; 1: 1017-23.
152. Kohn DB, Hershfield MS, Carbonaro D et al. T lymphocytes with a normal ADA gene accumulate after transplantation of transduced autologous umbilical cord blood CD34+ cells in ADA-deficient SCID neonates. Nat Med 1998; 4: 775-80.
153. Kohn DB. Adenosine deaminase gene therapy protocol revisited. Mol Ther 2002; 5: 96-7.
154. Arai F, Hirao A, Suda T. Regulation of hematopoiesis and its interaction with stem cell niches. Int J Hematol 2005; 82: 371-6.
155. Adams GB, Chabner KT, Alley IR et al. Stem cell engraftment at the endosteal niche is specified by the calcium-sensing receptor. Nature 2005; 439: 599-603.
156. Adams GB, Scadden DT. The hematopoietic stem cell in its place. Nat Immunol 2006; 7: 333-7.
157. Kollet O, Dar A, Shivtiel S et al. Osteoclasts degrade endosteal components and promote mobilization of hematopoietic progenitor cells. Nat Med 2006; 12: 657-64.
158. Purton L, Scadden DT. Osteoclasts eat stem cells out of house and home. Nat Med 2006; 12: 610-11.
159. Kiel MJ, Morrison SJ. Maintaining hematopoietic stem cells in the vascular niche. Immunity 2006; 25: 862-4.
160. Yaniv I, Stein J, Farkas DL, Askenasy N. The tale of early hematopoietic cell seeding in the bone marrow niche. Stem Cells Dev 2006; 15: 4-16.
161. Katayama Y, Battista M, Kao W-M et al. Signals from the sympathetic nervous system regulate hematopoietic stem cell egress from bone marrow. Cell 2006; 124: 407-21.
162. Kiel MJ, Radice GL, Morrison SJ. Lack of evidence that hematopoietic stem cells depend on N-cadherin-mediated adhesion to osteoblasts to their maintenance. Cell Stem Cell 2007; 1: 204-17.
163. Kim CH, Broxmeyer HE. Chemokines. Signal lamps for trafficking of T and B cells for development and effector function. J Leukoc Biol 1999; 65: 6-15.
164. Aiuti A, Webb IJ, Bleul C, Springer T, Guttierrez- Ramas JC. The chemokine SDF-1 is a chemoattractant for human CD34+ progenitors to peripheral blood. J Exp Med 1997; 185: 111-20.
165. Kim CH, Broxmeyer HE. In vitro behavior of hematopoietic progenitor cells under the influence of chemoattractants: stromal cell-derived factor-1, steel factor, and the bone marrow environment. Blood 1998; 91: 100-10.
166. Kim CH, Pelus LM, White JR, Broxmeyer HE. CKb-11/MIP-3b/ELC, a CC chemokine, is a chemoattractant with a specificity for macrophage progenitors amongst myeloid progenitor cells. J Immunol 1998; 25: 80-5.
167. Kim CH, Broxmeyer HE. SLC/exodus2/6Ckine/ TCA4 induces chemotaxis of hematopoietic progenitor cells: differential activity of ligands of CCR7, CXCR3, or CXCR4 in chemotaxis versus suppression of progenitor proliferation. J Leukoc Biol 1999; 66: 455-61.
168. Peled A, Petit I, Kollet O et al. Dependence of human stem cell engraftment and repopulation of NOD/SCID mice on CXCR4. Science 1999; 283: 845-8.
169. Kollet O, Petit I, Kahn J et al. Human CD34+ CXCR4- sorted cells harbor intracellular CXCR4, which can be functionally expressed and provide NOD/SCID repopulation. Blood 2002; 100: 2778-86.
170. Lapidot T, Kollet O. The essential roles of the chemokine SDF-1 and its receptor CXCR4 in human stem cell homing and repopulation of transplanted immune-deficient NOD/SCID and NOD/SCID/B2m(null) mice. Leukemia 2002; 16: 1992-2003.
171. Porecha NK, English K, Hangoc G, Broxmeyer HE, Christopherson KW. Enhanced functional response to CXCL12/SDF-1 through retroviral over-expression of CXCR4 on MO7e cells: implications for hematopoietic stem cell transplantation. Stem Cells Dev 2006; 15: 325-33.
172. Kim CH, Hangoc G, Cooper S et al. Altered responsiveness to chemokines due to targeted disruption of SHIP. J Clin Invest 1999; 104: 1751-9.
173. Kim CH, Qu CK, Hangoc G et al. Abnormal chemokine-induced responses of immature and mature hematopoietic cells from motheaten mice implicate the protein tyrosine phosphatase SHP-1 in chemokine responses. J Exp Med 1999; 190: 681-90.
174. Basu S, Broxmeyer HE. Transforming growth factor-a1 modulates responses of CD34+ cord blood cells to stromal cell derived factor-1/ CXCL12. Blood 2005; 106: 485-93.
175. Basu S, Ray N, Atkinson S, Broxmeyer HE. Protein phosphatase 2A plays an essential role in migration of CD34+ cells to SDF-1/CXCL12. J Immunol 2007; 179: 3075-85.
176. Lee Y, Gotoh A, Kwon HJ et al. Enhancement of intracellular signaling associated with hematopoietic progenitor cell survival in response to SDF- 1/CXCL12 in synergy with other cytokines. Blood 2002; 99: 4307-17.
177. Broxmeyer HE, Cooper S, Kohli L et al. Transgenic expression of stromal cell derived factor- 1/CXCL12 enhances myeloid progenitor cell survival/anti-apoptosis in vitro. Response to growth factor withdrawal and enhances myelopoiesis in vivo. J Immunol 2003; 170: 421-9.
178. Broxmeyer HE, Kohli L, Kim CH et al. Stromal cell derived factor-1/CXCL12 enhances survival/ anti-apoptosis of hematopoietic stem and myeloid progenitor cells: direct effects mediated through CXCR4 and Gai proteins. J Leuk Biol 2003; 73: 630-8.
179. Broxmeyer HE, Cooper S, Hangoc G, Kim CH. Stromal cell derived factor-1/CXCL12 selectively counteracts inhibitory effects of myelosuppressive chemokines on hematopoietic progenitor cell proliferation in vitro. Stem Cells Dev 2005; 14: 199-203.
180. Altenburg JD, Broxmeyer HE, Jin Q et al. A naturally occurring splice variant of CXCL12/ stromal cell-derived factor-1 is a potent HIV inhibitor with weak chemotaxis and cell survival activity. J Virol 2007; 81: 8140-8.
181. Nagasawa T, Hirota S, Tachibana K et al. Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1. Nature 1996; 382: 635-8.
182. Broxmeyer HE, Cooper S, Cacalano G et al. Interleukin- 8 receptor is involved in negative regulation of myeloid progenitor cells in vivo: evidence from mice lacking the murine IL-8 receptor homolog. J Exp Med 1996; 184: 1825-32.
183. Gao JL, Wynn TA, Chang Y et al. Impaired host defense, hematopoiesis, granulomatous inflammation and type 1/type 2 cytokine balance in mice lacking cc chemokine receptor 1. J Exp Med 1997; 185: 1959-68.
184. Broxmeyer HE, Christopherson KW II. Stromal cell derived factor-1/CXCL12, CXCR4 and CD26 in the mobilization and homing of hematopoietic Cord Blood Hematopoietic Cell Transplantation 575 stem and progenitor cells. In Special Issue: Lymphocyte Migration and Chemokines. Curr Med Chem Anti-Inflamm Anti-Allergy Agents 2004; 3: 303-11.
185. Christopherson KW II, Broxmeyer HE. Hematopoietic stem and progenitor cell homing, engraftment, and mobilization in the context of the CXCL12/SDF-1 -CXCR4 Axis. In: Broxmeyer HE, editor. Cord Blood: Biology, Immunology, Banking, and Clinical Transplantation. Bethesda, MD: AABB Press; 2004. pp. 65-86.
186. Campbell TB, Broxmeyer HE. CD26 inhibition and hematopoiesis: a novel approach to enhance transplantation. Special Issue: Dipeptidylpeptidase IV and Related Molecules in Health and Disease. Front Biosci 2007, 13: 1795-805.
187. Xia L, McDaniel JM, Yago T, Doeden A, McEver RP. Surface fucosylation of human cord blood cells augments binding to P-selectin and Eselectin and enhances engraftment in bone marrow. Blood 2004; 15: 3091-6.
188. Christopherson KW II, Hangoc G, Broxmeyer HE. Cell surface petidose CD26/DPPIV regulates CXCL12/SDF-1a mediated chemotaxis of human CD34+ progenitor cells. J Immunol 2002; 169: 7000-8.
189. Christopherson KW II, Hangoc G, Mantel C, Broxmeyer HE. Modulation of hematopoietic stem cell homing and engraftment by CD26. Science 2004; 305: 1000-3.
190. Campbell TB, Hangoc G, Liu Y, Pollok K, Broxmeyer HE. Inhibition of CD26 in human cord blood CD34+ cells enhances their engraftment of nonobese diabetic/severe combined immunodeficiency mice. Stem Cells Dev 2007; 16: 347-54.
191. Christopherson KW II, Paganessi LA, Napier S, Porecha NK. CD26 inhibition on CD34+ or lineage- human umbilical cord blood donor hematopoietic stem cells/hematopoietic progenitor cells improves long-term engraftment into NOD/ SCID/Beta2null immunodeficient mice. Stem Cells Dev 2007; 16: 355-60.
192. Kawai T, Choi U, Liu P-C et al. Diprotin A infusion with nonobese diabetic/severe combined immunodeficiency mice markedly enhances engraftment of human mobilized CD34+ peripheral blood cells. Stem Cells Develop 2007; 16: 361-70.
193. Broxmeyer HE, Hangoc G, Cooper S et al. AMD3100 and CD26 modulate the mobilization, engraftment, and survival of hematopoietic stem and progenitor cells mediated by the SDF-1/ CXCL12-CXCR4 axis. Ann NY Acad Sci U S A 2007; 1106: 1-19.
194. Jung CW, Beard BC, Morris JC et al. Hematopoietic stem cell engraftment: a direct comparison between intramarrow and intravenous injection in nonhuman primates. Exp Hematol 2007; 35: 1132-9.
195. Inaba M, Adachi Y, Hisha H et al. Extensive studies on perfusion method plus intra-bone marrow-bone marrow transplantation using cynomolgus monkeys. Stem Cells 2007; 25: 2098-103.
196. Socie G, Gluckman E, Carosella E et al. Search for maternal cells in human umbilical cord blood by polymerase chain reaction amplification of two minisatellite sequences. Blood 1994; 83: 340-4.
197. Hall JM, Lingenfelter P, Adams SL et al. Detection of maternal cells in human umbilical cord blood using fluorescence in situ hybridization. Blood 1995; 86: 2829-32.
198. Petit T, Gluckman E, Carosella E et al. A highly sensitive polymerase chain reaction method reveals the ubiquitous presence of maternal cells in human umbilical cord blood. Exp Hematol 1995; 23: 1601-5.
199. Poli F, Crespiatico L, Lecchi L et al. Highly sensitive chemiluminescent method for the detection of maternal cell contamination in human cord blood stored for allotransplantation: the experience of the Milano cord blood bank [Letter]. Blood 1997; 89: 3061-2.
200. Fietz T, Hilgenfeld E, Berdel WE et al. Ex vivo expansion of human umbilical cord blood does not lead to co-expansion of contaminating maternal mononuclear cells. Bone Marrow Transplant 1997; 20: 1019-26.
201. Roncarolo MG, Vaccarinom E, Saracco P et al. Immunologic properties of cord blood. In: Broxmeyer HE, editor. Cellular Characteristics of Cord Blood and Cord Blood Transplantation. Bethesda, MD: AABB Press; 1998. pp. 67-81.
202. Roncarolo MG, Vaccarinom E, Saracco P et al. Immunologic properties of cord blood. In: Broxmeyer HE, editor. Cellular Characteristics of Cord Blood and Cord Blood Transplantation. Bethesda, MD: AABB Press; 1998. pp. 67-81.
203. Risdon G, Gaddy J, Broxmeyer HE. Allogeneic responses of human umbilical cord blood. Blood Cells 1994; 20: 566-70.
204. Kim YJ, Broxmeyer HE. Cytotoxic T lymphocytes and umbilical cord blood transplantation. In: Broxmeyer HE, editor. Cord Blood: Biology, Immunology, Banking, and Clinical Transplantation. Bethesda, MD: AABB; 2004. pp. 199-217.
205. Risdon G, Gaddy J, Horie M, Broxmeyer HE. Alloantigen priming induces a state of unresponsiveness in human umbilical cord blood T cells. Proc Natl Acad Sci U S A 1995; 92: 2413-17.
206. Porcu P, Gaddy J, Broxmeyer HE. Alloantigeninduced unresponsiveness in cord blood T lymphocytes is associated with defective activation of Ras. Proc Natl Acad Sci U S A 1998; 95: 4538-43.
207. Hodge MR, Ranger AM, Charles de la Brousse F et al. Hyperproliferation and dysregulation of IL- 4 expression in NF-ATp-deficient mice. Immunity 1996; 4: 397-405.
208. Kadereit S, Mohammad SF, Miller RE et al. Reduced NFAT1 protein expression in human umbilical cord blood T lymphocytes. Blood 1999; 94: 3101-7.
209. Sato K, Kawasaki H, Nagayama H et al. Chemokine receptor expressions and responsiveness of cord blood T cells. J Immunol 2001; 166: 1659-66.
210. Kim Y-J, Brutkiewicz R, Broxmeyer HE. Role of 4-1BB (CD137) in the functional activation of cord blood CD28-CD8+ T cells. Blood 2002; 100: 3253-60.
211. Kim Y-J, Stringfield TM, Chen Y, Broxmeyer HE. Modulation of cord blood CD8+ T-cell effector differentiation by TGF-ß1 and 4-1BB costimulation. Blood 2005; 105: 274-81.
212. Robinson KL, Ayello J, Hughes R et al. Ex vivo expansion, maturation, and activation of umbilical cord blood-derived T lymphocytes with IL-2, IL- 12, anti-CD3, and IL-7. Potential for adoptive cellular immunotherapy post-umbilical cord blood transplantation. Exp Hematol 2002; 30: 245-51.
213. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003; 299: 1057-61.
214. Fontenot JD, Gavin A, Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 2003; 4: 330-6.
215. Lim HW, Broxmeyer HE, Kim CH. Regulation of trafficking receptor expression in human forkhead box P3+ regulatory T cells. J Immunol 2006; 177: 840-51.
216. Gaddy J, Porcu P, Broxmeyer HE. Clinical and basic science studies of human umbilical cord blood: implications for the GVL effect following cord blood transplantation. In: Barrett J, Jiang YZ, editors. Allogeneic Immunotherapy for Malignant Disease. New York: Marcel Dekker; 2000. pp. 267-84.
217. Gaddy J, Broxmeyer HE. Cord blood natural killer cells. Implication for cord blood transplantation and insights into natural killer cell differentiation. In: Broxmeyer HE, editor. Cellular Characteristics of Cord Blood and Cord Blood Transplantation. Bethesda, MD: AABB Press; 2000. pp. 83-111.
218. Gaddy J, Risdon G, Broxmeyer HE. Cord blood natural killer cells are functionally and phenotypically immature but readily respond to interleukin- 2 and interleukin-12. J Interferon Cytokine Res 1995; 15: 527-36.
219. Gaddy J, Broxmeyer HE. Cord blood CD16+56- cells with low lytic activity are possible precursors of mature natural killer cells. Cell Immunol 1997; 180: 132-42.
220. Borras FE, Matthews NC, Lowdell MW, Navarrete CV. Identification of both myeloid CD11c+ and lymphoid CD11c- dendritic cell subsets in cord blood. Br J Haematol 2001; 113: 925-31.
221. Kim Y-J, Li G, Broxmeyer HE. 4-1BB ligand stimulation enhances myeloid dendritic cell maturation from human umbilical cord blood CD34+ progenitor cells. J Hematother Stem Cell Res 2002; 11: 895-904.
222. Canque B, Camus S, Dalloul A et al. Characterization of dendritic cell differentiation pathways from cord blood CD34+CD7+CD45RA+ hematopoietic progenitor cells. Blood 2000; 96: 3748-56.
223. Li G, Kim YJ, Broxmeyer HE. Macrophage colony-stimulating factor drives cord blood monocyte differentiation into IL-10highIL-12absent dendritic cells with tolerogenic potential. J Immunol 2005; 174: 4706-17.
224. Li G, Abediankenari S, Kim YJ et al. TGF-ß combined with M-CSF induces generation of immune inhibitory cord blood dendritic cells capable of enhancing cytokine-stimulated ex-vivo expansion of myeloid progenitors. Blood 2007; 110: 2872-9.
225. Li G, Basu S, Han M-K, Kim Y-J, Broxmeyer HE. Influence of ERK activation on decreased chemotaxis of mature human cord blood monocytederived dendritic cells to CCL19 and CXCL12. Blood 2007; 109: 3173-6.
226. Barker JN. Umbilical cord blood (UCB) transplantation: an alternative to the use of unrelated volunteer donors? Hematology Am Soc Hematol Educ Program 2007; 55-61.
227. Wagner J, Champlin R, Petz LD. Fifth annual international umbilical cord blood transplantation 576 Chapter 39 symposium, Los Angeles, California, May 11-12, 2007: symposium summary. Biol Blood Marrow Transpl 2007; 13: 1380-92.
228. Kamani N, Spellman S, Katovich Hurley C et al. State of the art review: HLA matching and outcome of unrelated donor umbilical cord blood transplants [Editorial]. Biol Blood Marrow Transplant 2008; 14: 1-6.
229. Gluckman E, Rocha V, Ionescu I et al. Results of unrelated cord blood transplant in Fanconi anemia patients: risk factor analysis for engraftment and survival. Biol Blood Marrow Transplant 2007; 13: 1073-82.
230. Komanduri KV, St John LS, de Lima M et al. Delayed immune reconstitution after cord blood transplantation is characterized by impaired thymopoiesis and late memory T-cell skewing. Blood 2007; 110: 4543-51.
231. Szabolcs P, Niedzwiecki D. Immune reconstitution after unrelated cord blood transplantation. Cytotherapy 2007; 9: 111-22.
232. Szabolcs P, Niedzwiecki D. Immune reconstitution in children after unrelated cord blood transplantation. Biol Blood Marrow Transplant 2008; 14: 66-72.
233. Walker CM, van Burik JAH, De For TE, Weisdorf DJ. Cytomegalovirus infection after allogeneic transplantation: comparison of cord blood with peripheral blood and marrow graft sources. Biol Blood Marrow Transplant 2007; 13: 1106-15.
234. Arora M, Nagaraj S, Wagner JE et al. Chronic graft-versus-host disease (cGVHD) following unrelated donor hematopoietic stem cell transplantation (HSCT): higher response rate in recipients of unrelated donor (URD) umbilical cord blood (UCB). Biol Blood Marrow Transplant 2007; 13: 1145-52.
235. Barrett J. Are UC blood transplants prone to developing leukemia? Cytotherapy 2007; 9: 611-12.
236. Ren G, Zhang L, Zhao X et al. Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell 2008; 2: 141-50.
237. Orazi A, Braun SE, Broxmeyer HE. Commentary: Immunohistochemistry represents a useful tool to study human cell engraftment in SCID mice transplantation models. Blood Cells 1994; 20: 323-30.